Primary Treatment Selection for Clinically Node‐Negative Merkel Cell Carcinoma of the Head and Neck
- 20 October 2020
- journal article
- research article
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 164 (6) , 1214-1221
Abstract
Objective: Merkel cell carcinoma practice guidelines recommend sentinel lymph node biopsy after wide local excision for the initial management of clinically node‐negative disease without distant metastases (cN0M0). Despite guideline publication, treatment selection remains variable. We hypothesized that receipt of guideline‐recommended care would be more common in patients evaluated at academic centers and institutions with high melanoma case volumes and that such therapy would be associated with improved overall survival.Study Design: Retrospective cohort analysis.Setting: The National Cancer Database from 2004 to 2015.Methods: A total of 3500 patients were included. We utilized Kaplan‐Meier analysis and logistic and Cox proportional hazard regressions. Survival analysis was performed on inverse probability–weighted cohorts.Results: There has been a trend toward evaluation at academic programs at a rate of 1.58% of patients per year (95% CI, 1.06%‐2.11%) since 2004. However, the percentage of patients receiving guideline‐compliant primary tumor excision and lymph node evaluation has plateaued at approximately 50% since 2012. Guideline‐compliant surgical management was more commonly provided to patients evaluated at academic programs than nonacademic programs but only when those institutions had a high melanoma case volume (odds ratio, 2.01; 95% CI, 1.62‐2.48). Receipt of guideline‐compliant primary tumor excision and lymph node evaluation was associated with improved overall survival (hazard ratio, 0.70; 95% CI, 0.64‐0.76).Conclusion: Facility factors affect rates of receipt of guideline‐compliant initial surgical management for patients with node‐negative Merkel cell carcinoma. Given the survival benefit of such treatment, patients may benefit from care at hospitals with high melanoma case volumes.Keywords
Funding Information
- Yale University (William U. Gardner Memorial Student ResearchFellowship at the Yale University School of Medicine)
- Yale Cancer Center (Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program)
This publication has 34 references indexed in Scilit:
- Merkel Cell Carcinoma: Interdisciplinary Management of a Rare DiseaseJournal of Skin Cancer, 2013
- Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Merkel Cell Carcinoma: Incidence, Mortality, and Risk of Other CancersJNCI: Journal of the National Cancer Institute, 2010
- Clinical Recognition, Diagnosis, and Staging of Merkel Cell Carcinoma, and the Role of the Multidisciplinary Management TeamCurrent Problems in Cancer, 2010
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008
- Understanding high‐quality cancer careCancer, 2008
- Merkel cell carcinoma: Changing incidence trendsJournal of Surgical Oncology, 2004
- Multimodality Treatment of Merkel Cell Carcinoma: Case Series and Literature Review of 1024 CasesAnnals of Surgical Oncology, 2001
- Merkel Cell Carcinoma Arising in the Head and NeckAmerican Journal of Clinical Oncology, 2001
- Trabecular Carcinoma of the SkinArchives of Dermatology, 1972